Interleukin-6 serum levels are associated with disease features and cardiovascular risk in patients with systemic sclerosis.

IF 3.4 4区医学 Q2 RHEUMATOLOGY

Clinical and experimental rheumatology Pub Date : 2024-08-01 Epub Date: 2023-12-04 DOI:10.55563/clinexprheumatol/3e8ufg

Zeina Ibrahim-Achi, Antonia de Vera-González, Alejandra González-Delgado, Raquel López-Mejías, Miguel Ángel González-Gay, Iván Ferraz-Amaro

{"title":"Interleukin-6 serum levels are associated with disease features and cardiovascular risk in patients with systemic sclerosis.","authors":"Zeina Ibrahim-Achi, Antonia de Vera-González, Alejandra González-Delgado, Raquel López-Mejías, Miguel Ángel González-Gay, Iván Ferraz-Amaro","doi":"10.55563/clinexprheumatol/3e8ufg","DOIUrl":null,"url":null,"abstract":"Objectives: Systemic sclerosis (SSc) is a chronic multisystem disease characterised by microcirculatory vascular dysfunction and progressive fibrosis of the skin and internal organs. Interleukin-6 (IL-6) is a proinflammatory cytokine that has been implicated in the pathogenesis of several autoimmune diseases and in the initiation and progression of the cardiovascular disease. In the present work we aimed to study the relationship of IL-6 with clinical manifestations and the cardiovascular risk in patients with SSc.Methods: We carried out a cross-sectional study that included 53 individuals with SSc. A multivariate analysis was performed to study the relationship between IL-6 and disease characteristics and cardiovascular risk assessed by Systematic Coronary Risk Estimation (SCORE2) in SSc.Results: The presence of digital ulcers, calcinosis, and anti-Scl70 antibody was associated with higher levels of IL-6. This was also the case for functional respiratory parameters where this association was found to be significant and negative after correction for covariates. In addition, the SCORE2 cardiovascular risk algorithm showed a positive and significant association with circulating IL-6.Conclusions: IL-6 levels are associated with disease manifestations and cardiovascular risk in patients with SSc.","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55563/clinexprheumatol/3e8ufg","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Systemic sclerosis (SSc) is a chronic multisystem disease characterised by microcirculatory vascular dysfunction and progressive fibrosis of the skin and internal organs. Interleukin-6 (IL-6) is a proinflammatory cytokine that has been implicated in the pathogenesis of several autoimmune diseases and in the initiation and progression of the cardiovascular disease. In the present work we aimed to study the relationship of IL-6 with clinical manifestations and the cardiovascular risk in patients with SSc.

Methods: We carried out a cross-sectional study that included 53 individuals with SSc. A multivariate analysis was performed to study the relationship between IL-6 and disease characteristics and cardiovascular risk assessed by Systematic Coronary Risk Estimation (SCORE2) in SSc.

Results: The presence of digital ulcers, calcinosis, and anti-Scl70 antibody was associated with higher levels of IL-6. This was also the case for functional respiratory parameters where this association was found to be significant and negative after correction for covariates. In addition, the SCORE2 cardiovascular risk algorithm showed a positive and significant association with circulating IL-6.

Conclusions: IL-6 levels are associated with disease manifestations and cardiovascular risk in patients with SSc.

查看原文本刊更多论文

白细胞介素-6 血清水平与系统性硬化症患者的疾病特征和心血管风险有关。

目的：系统性硬化症（SSc）是一种慢性多系统疾病，其特征是微循环血管功能障碍以及皮肤和内脏器官的进行性纤维化。白细胞介素-6（IL-6）是一种促炎细胞因子，与多种自身免疫性疾病的发病机制以及心血管疾病的发生和发展有关。在本研究中，我们旨在研究 IL-6 与 SSc 患者的临床表现和心血管风险之间的关系：方法：横断面研究，包括 53 名 SSc 患者。方法：横断面研究纳入了53名SSc患者，通过多变量分析研究了IL-6与SSc患者疾病特征和系统冠状动脉风险评估（SCORE2）评估的心血管风险之间的关系：结果：出现数字溃疡、钙化和抗Scl70抗体与较高的IL-6水平有关。呼吸功能参数也是如此，在校正协变量后发现这种关联显著且呈负相关。此外，SCORE2心血管风险算法与循环IL-6呈显著正相关：IL-6水平与SSc患者的疾病表现和心血管风险有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and experimental rheumatology 医学-风湿病学

CiteScore

6.10

自引率

18.90%

发文量

377

审稿时长

3-6 weeks

期刊介绍： Clinical and Experimental Rheumatology is a bi-monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983.